Abstract: There is provided a method for synthesizing an alkenoic acid, in particular acrylic acid comprising the step of oxidizing an alkenyl alcohol in the presence of a metal oxide catalyst to form the alkenoic acid. The invention further provides a step of deoxydehydrating a polyol, including glycerol to obtain said alkenyl alcohol including an allyl alcohol.

Abstract: There is provided compound for use in therapy, the compound comprising repeating units of hydrophilic heterocyclic amine monomers that are coupled by hydrophobic linkers selected to confer a therapeutic effect. There is also provided the use of the above compound in the manufacture of a medicament for the treatment of a fungal infection and a method of treating a fungal infection using the above compound.

Abstract: There is provided a one-pot process for the conversion of sugars to furancarboxylic acids, such as 2,5-furancarboxylic acid (FDCA), in a triphasic system (e.g. water or tetraethylammonium bromide (TEAB)—methyl isobutyl ketone (MIBK)—water). In this reaction setup, sugars are first converted to 5-hydroxymethylfurfural (HMF) in a first phase. Then HMF is then extracted into a second phase and transferred to a third phase of water. In the third phase HMF is converted to the furancarboxylic acid. The overall acid yields obtainable are between about 78% and 50% for conversion from fructose and glucose, respectively. The invention further relates to an apparatus for the triphasic reaction. The apparatus comprises two chambers which allow for the chemically separated reaction of the sugars and the intermediate of the sugars to form the final product in one process. The process according to the invention may be useful for industrial fabrication.

Abstract: The present invention relates to antimicrobial imidazolium compounds having the structure of Formula (I) wherein R is an optionally substituted aliphatic group that is linear, cyclic, saturated, unsaturated or any combination thereof; n is an integer of at least 1; and X is an anionic counterion. The present invention also relates to pharmaceutical composition comprising the compound, a gel comprising the compound, uses of the compound as an antibiotic and methods for the preparation of the gels.

Abstract: The present disclosure relates to a polymer material comprising mesopores extending between melamine-formaldehyde co-polymer nano-particles and wherein micropores extend within the co-polymer nano-particles, methods of producing the same and uses thereof.

Abstract: A method for synthesizing a sugar alcohol comprising the step of hydrolyzing a polysaccharide in the presence of hydrogen ions (H+), an alcoholic reducing agent and a hydrogen transfer catalyst to form the sugar alcohol.

Abstract: There is provided compound for use in therapy, the compound comprising repeating units of hydrophilic heterocyclic amine monomers that are coupled by hydrophobic linkers selected to confer a therapeutic effect. There is also provided the use of the above compound in the manufacture of a medicament for the treatment of a fungal infection and a method of treating a fungal infection using the above compound.

Abstract: The present invention provides a method of synthesizing an ester of a saturated carboxylic acid from a saturated polyhydroxycarboxylic acid by performing a deoxydehydration reaction and a hydrogen transfer reaction.

Abstract: The present disclosure relates to a polymer material comprising mesopores extending between melamine-formaldehyde co-polymer nano-particles and wherein micropores extend within the co-polymer nano-particles, methods of producing the same and uses thereof.

Abstract: There is presently provided methods for delivering an anti-fibrotic or anti-cancer agent to a cell. The methods comprise contacting a cell with an effective amount of imidazolium and imidazolinium compounds as described herein, including imidazolium and imidazolinium salts.

Abstract: There is provided compound for use in therapy, the compound comprising repeating units of hydrophilic heterocyclic amine monomers that are coupled by hydrophobic linkers selected to confer a therapeutic effect. There is also provided the use of the above compound in the manufacture of a medicament for the treatment of a fungal infection and a method of treating a fungal infection using the above compound.

Abstract: The invention relates to a polyisocyanurate comprising isocyanurate rings linked by linker groups coupled to the nitrogen atoms of said rings. The polyisocyanurate may be microporous or mesoporous or both microporous and mesoporous.

Abstract: A method of acetalizing an aldehyde comprising reacting said aldehyde with an alcohol in the presence of a polymeric catalyst to form an acetal wherein the polymeric catalyst is a mesoporous poly-melamine-formaldehyde polymer.

Abstract: The present invention relates to a method for synthesizing an optionally substituted furoic acid by dehydrating a biomass and oxidizing the optionally substituted furan derived from the dehydration reaction. Water extraction has been incorporated as a step between the dehydration and the oxidation in order to purify the intermediate optionally substituted furan before having it oxidized. Prior to this water extraction, the organic solvent used for dehydration may be separated by evaporation. The provision of the water extraction allows impurities to be separated from the intermediate optionally substituted furan.

Abstract: The present invention provides a polymer comprising an aliphatic backbone having a plurality of aromatic rings bonded thereon, said plurality of aromatic rings comprising a first aromatic ring type that has an alkyl halide group substitution on the aromatic ring and a second aromatic ring type that has an optionally substituted ammonium halide group substitution on the aromatic ring. The present invention also provides a method for making an optionally substituted furan, the method comprising the step of subjecting a sugar to a dehydration reaction in the presence of a catalyst comprising said polymer.

Abstract: There is provided a process for producing an aminopropyne or an enaminone comprising the step of reacting a metal acetylide, an amine and a carbonyl-containing compound in the presence of a transition metal catalyst. There is also provided a process for producing an aminopropyne comprising the step of reacting a metal acetylide, an amine and a halide-containing compound in the presence of a transition metal catalyst at a reaction temperature of 50° C. to 150° C. There are also provided processes to further synthesize the aminopropyne produced to obtain a butyneamine, another aminopropyne or a triazol.

Abstract: There is presently provided methods for delivering an anti-fibrotic or anti-cancer agent to a cell. The methods comprise contacting a cell with an effective amount of imidazolium and imidazolinium compounds as described herein, including imidazolium and imidazolinium salts.

Abstract: There is provided a process for producing an aminopropyne or an enaminone comprising the step of reacting a metal acetylide, an amine and a carbonyl-containing compound in the presence of a transition metal catalyst. There is also provided a process for producing an aminopropyne comprising the step of reacting a metal acetylide, an amine and a halide-containing compound in the presence of a transition metal catalyst at a reaction temperature of 50° C. to 150° C. There are also provided processes to further synthesize the aminopropyne produced to obtain a butyneamine, another aminopropyne or a triazol.

Abstract: There is provided compound for use in therapy, the compound comprising repeating units of hydrophilic heterocyclic amine monomers that are coupled by hydrophobic linkers selected to confer a therapeutic effect. There is also provided the use of the above compound in the manufacture of a medicament for the treatment of a fungal infection and a method of treating a fungal infection using the above compound.

Abstract: There is presently provided methods for delivering an anti-fibrotic or anti-cancer agent to a cell. The methods comprise contacting a cell with an effective amount of imidazolium and imidazolinium compounds as described herein, including imidazolium and imidazolinium salts.